Clinical activity observed in all three mesothelin-expressing tumor types treated
- Gavo-cel disease control rate (DCR) 81% with tumor regression in 15 of 16 evaluable patients
- Overall response rate (ORR) 31% in patients infused with gavo-cel following lymphodepletion
- Meaningful survival benefit at 11.2 months for patients with refractory mesothelioma
- Recommended Phase 2 Dose (RP2D) being refined after identification of the Maximum Tolerated Dose (MTD)
- TCR2 to host a conference call on Friday, September 17 at 9:00a.m. ET
https://finance.yahoo.com/news/tcr-therapeutics-announces-positive-interim-113000844.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.